The inventors of Rice University’s tiny, cancer-killing “drug factory” implants are teaming with Baylor College of Medicine surgeons to create a version of the technology that can heal injuries caused by heart attacks.
Someone has a heart attack every 40 seconds in the United States. An artery that supplies blood to the heart becomes blocked, and heart muscle tissue dies. In up to 30% of patients, this can lead to heart failure, where the heart cannot pump with the necessary strength to supply the body's needs.
Rice and Baylor’s new treatment will target inflammation that can worsen the downward spiral of heart failure.
Veiseh is partnering with Baylor cardiothoracic surgeon Ravi Ghanta on the project, which is funded by a grant from the American Heart Association. The tens of thousands will load the cytokine-producing cells into 1.5-millimeter-wide alginate beads that can be placed directly on the surface of the heart with minimally invasive surgery. The project includes animal testing could support a future application for a human clinical trial, Veiseh said.
“Once in place, the beads act as ‘drug factories’ that deliver highly localized and concentrated doses of cytokines precisely where they’re needed,” said Ghanta.
Veiseh said the beads will shield the cytokine-producing cells from the immune system and should allow the drug factories to keep working for weeks.
“Our goal is to deliver effective doses of cytokines for up to six months,” Veiseh said.
In a previous study, Ghanta and Veiseh showed beads loaded with stem cells produced 2.5 times greater heart healing in rodents following heart attack than treatment with stem cells unshielded by beads.
Veiseh joined Rice in 2016 thanks to a recruitment grant from the Cancer Prevention and Research Institute of Texas (CPRIT). He has spent years developing encapsulation systems that avoid activating the immune system, and is also using the technology to create treatments for cancer and Type 1 diabetes.
Avenge Bio, a Massachusetts-based startup Veiseh co-founded, this week announced plans to begin a human clinical trial for ovarian cancer later this year. It is the first clinical trial of the “drug factory” technology.
Source: Rice University